Matthew P Patricelli
Overview
Explore the profile of Matthew P Patricelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
2283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klebba J, Roy N, Bernard S, Grabow S, Hoffman M, Miao H, et al.
bioRxiv
. 2025 Jan;
PMID: 39763752
Genetic disruption of the RAS binding domain (RBD) of PI 3-kinase (PI3K) prevents the growth of mutant RAS driven tumors in mice and does not impact PI3K's role in insulin...
2.
Baltgalvis K, Lamb K, Symons K, Wu C, Hoffman M, Snead A, et al.
Nature
. 2024 Jul;
631(8021):E12.
PMID: 38961306
No abstract available.
3.
Baltgalvis K, Lamb K, Symons K, Wu C, Hoffman M, Snead A, et al.
Nature
. 2024 Apr;
629(8011):435-442.
PMID: 38658751
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with...
4.
Kavanagh M, Horning B, Khattri R, Roy N, Lu J, Whitby L, et al.
Nat Chem Biol
. 2022 Sep;
18(11):1288.
PMID: 36180594
No abstract available.
5.
Kavanagh M, Horning B, Khattri R, Roy N, Lu J, Whitby L, et al.
Nat Chem Biol
. 2022 Sep;
18(12):1388-1398.
PMID: 36097295
The Janus tyrosine kinase (JAK) family of non-receptor tyrosine kinases includes four isoforms (JAK1, JAK2, JAK3, and TYK2) and is responsible for signal transduction downstream of diverse cytokine receptors. JAK...
6.
Lu W, Kostic M, Zhang T, Che J, Patricelli M, Jones L, et al.
RSC Chem Biol
. 2021 Aug;
2(2):670-671.
PMID: 34459829
[This corrects the article DOI: 10.1039/D0CB00222D.].
7.
Lu W, Kostic M, Zhang T, Che J, Patricelli M, Jones L, et al.
RSC Chem Biol
. 2021 Aug;
2(2):354-367.
PMID: 34458789
Targeted covalent inhibitors have regained widespread attention in drug discovery and have emerged as powerful tools for basic biomedical research. Fueled by considerable improvements in mass spectrometry sensitivity and sample...
8.
Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X, et al.
Cell
. 2018 Jan;
172(3):578-589.e17.
PMID: 29373830
KRAS was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active...
9.
Okerberg E, Hainley A, Brown H, Aban A, Alemayehu S, Shih A, et al.
PLoS One
. 2017 Feb;
12(2):e0172649.
PMID: 28199383
[This corrects the article DOI: 10.1371/journal.pone.0152934.].
10.
Matthews J, Bhatt S, Patricelli M, Nomanbhoy T, Jiang X, Natkunam Y, et al.
Blood
. 2016 May;
128(2):239-48.
PMID: 27151888
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, yet 40% to 50% of patients will eventually succumb to their disease, demonstrating a pressing need for...